Top

Published in:

01-03-2009 | original article

Use of Positron Emission Tomography in Surgery Follow-Up of Esophageal Cancer

Authors: P. Teyton, J. P. Metges, A. Atmani, V. Jestin-Le Tallec, A. Volant, D. Visvikis, J. P. Bail, O. Pradier, P. Lozac’h, Catherine Cheze Le Rest

Published in: Journal of Gastrointestinal Surgery | Issue 3/2009

Abstract

Introduction

Although the prognosis of patients with esophageal cancer has been improved by extended dissection, the incidence of recurrence still remains high. In esophageal cancer, positron emission tomography (PET) using ¹⁸F-fluorodeoxyglucose (FDG) already demonstrated to be useful for initial staging and monitoring response to therapy. This prospective study compared the ability of FDG-PET and conventional imaging to detect early recurrence of esophageal cancer after initial surgery in asymptomatic patients.

Materials and Methods

Between October 2003 and September 2006, 41 patients with esophageal cancer were included in a prospective study after initial radical esophagectomy. FDG-PET, thoracoabdominal computed tomography (CT), abdominal ultrasonography, and endoscopy were performed every 6 months after initial treatment.

Results and Discussion

Twenty-three patients had recurrent disease (56%), mostly within the first 6 months after surgery (70%). Despite two false-positive scans due to postoperative changes, FDG-PET was more accurate than CT (91% vs. 81%, p = 0.02) for the detection of recurrence with a sensitivity of 100% (vs. 65%), a specificity of 85% (vs. 91%), and a negative predictive value of 100% on a patient-by-patient-based analysis. For the detection of locoregional recurrence, FDG-PET was more accurate than CT (96.2% vs. 88.9%). FDG-PET was also more accurate than CT for the detection of distant metastases (92.5% vs. 84.9%), especially when involving either bones (100%) or liver (98.1%). A lower sensitivity of FDG-PET (57%) for the early detection of small lung metastases did not affect patient management (accuracy = 92.5%).

Conclusion

FDG-PET appears to be very useful for the systematic follow-up of asymptomatic patients after esophagectomy with an initial scan performed 6 months after surgery.

Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–2317. doi:10.1200/JCO.2005.00.034.PubMedCrossRef

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–1168. doi:10.1200/JCO.2005.04.7118.PubMedCrossRef

Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110–4117. doi:10.1200/JCO.2007.12.0881.PubMedCrossRef

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–234. doi:10.1016/S1470-2045(07)70039-6.PubMedCrossRef

Triboulet JP, Mariette C. Oesophageal squamous cell carcinoma stade III. State of surgery after radiochemotherapy (RCT). Cancer Radiother 2006;10:456–461. doi:10.1016/j.canrad.2006.08.002.PubMed

Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H, Akazawa K. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994;219:310–316. doi:10.1097/00000658-199403000-00012.PubMedCrossRef

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364–372. doi:10.1097/00000658-199409000-00012.PubMedCrossRef

Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg 1996;182:340–346.PubMed

Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S, Toh Y, Fujii T, Tou U, Shirouzu K. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg 1997;21:275–281. doi:10.1007/s002689900228.PubMedCrossRef

10.

Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000;191:143–148. doi:10.1016/S1072-7515(00)00349-5.PubMedCrossRef

11.

Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616–1623. doi:10.1002/cncr.11228.PubMedCrossRef

12.

Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Ohtomo K. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. Dis Esophagus 2005;18:215–220. doi:10.1111/j.1442-2050.2005.00502.x.PubMedCrossRef

13.

Komatsu S, Shioaki Y, Ichikawa D, Hamashima T, Kan K, Ueshima Y, Koide K, Lee CJ, Ikeda E, Mutoh F, Kurioka H, Oka T, Yamagishi H. Survival and clinical evaluation of salvage operation for cervical lymph node recurrence in esophageal cancer. Hepatogastroenterology 2005;52:796–799.PubMed

14.

Kubota K, Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Nakanishi Y, Iinuma G. Surgical therapy for recurrent esophageal cancers at anastomoses after esophagectomy. Hepatogastroenterology 2001;48:1364–1367.PubMed

15.

Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Uenosono Y, Ishigami S, Owaki T, Aikou T. The role of salvage surgery for recurrence of esophageal squamous cell cancer. Eur J Surg Oncol 2006;32:544–547. doi:10.1016/j.ejso.2006.02.014.PubMedCrossRef

16.

Homs M, v d Gaast A, Siersema P, Steyerberg E, Kuipers E. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006;18:CD004063H.

17.

Vidal O, Soriano-Izquierdo A, Pera M, Elizalde J, Palacin A, Castells A, Pique J, Volant A, Metges J. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg 2008;12:1005–1014. doi:10.1007/s11605-007-0336-3.PubMedCrossRef

18.

Atmani A, Topart P, Vandenbroucke F, Louzi A, Ferrand L, Lozac’h P. Metachronous cancer of gastroplasty after esophagectomy. Dis Esophagus 2006;19:512–515. doi:10.1111/j.1442-2050.2006.00623.x.PubMedCrossRef

19.

Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202–3210.PubMed

20.

Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 2004;45:980–987.PubMed

21.

Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521–527.PubMed

22.

Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1232–1241. doi:10.1016/j.jtcvs.2004.12.042.PubMedCrossRef

23.

Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300–309. doi:10.1097/00000658-200103000-00002.PubMedCrossRef

24.

Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797–805. doi:10.1016/S1470-2045(07)70244-9.PubMedCrossRef

25.

Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058–3065.PubMed

26.

Cheze-Le Rest C, Metges JP, Teyton P, Jestin-Le Tallec V, Lozac’h P, Volant A, Visvikis D. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 2008;29:628–635.PubMedCrossRef

27.

Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199–4208. doi:10.1200/JCO.2002.02.590.PubMedCrossRef

28.

Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381. doi:10.1182/blood-2005-01-0272.PubMedCrossRef

29.

Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, Sybrecht GW, Kirsch CM. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13–21. doi:10.1007/s00259-005-1919-4.PubMedCrossRef

30.

Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136–1143. doi:10.1200/JCO.2005.06.129.PubMedCrossRef

31.

Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D, Mortelmans L. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000;120:1085–1092. doi:10.1067/mtc.2000.110464.PubMedCrossRef

32.

Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 2004;91:1004–1009. doi:10.1002/bjs.4595.PubMedCrossRef

33.

Surti S, Karp JS. Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med 2004;45:1040–109.PubMed

34.

Visvikis D, Turzo A, Gouret S, Damien P, Lamare F, Bizais Y, Cheze-Le Rest C. Characterisation of SUV accuracy in FDG PET using 3D RAMLA and the Philips Allegro PET scanner. J Nucl Med 2004;45:103P.

35.

Greene F, Page D, Flemming I. AJCC cancer staging manual. New York: Springer, 2002.CrossRef

36.

Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 1986;110:685–686.PubMed

37.

Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81. doi:10.2307/2281868.CrossRef

38.

Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed C, Goldberg R, Rich T, Kiel K, Mayer R. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. J Clin Oncol 2006;24:4012.

39.

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004;198:205–211. doi:10.1016/j.jamcollsurg.2003.10.005.PubMedCrossRef

40.

Chen G, Wang Z, Liu XY, Liu FY. Recurrence patterns of esophageal cancer after Ivor-Lewis esophagectomy—a report of 196 cases. Ai Zheng 2006;25:96–99.PubMed

41.

Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005;6:864–870. doi:10.1016/S1470-2045(05)70347-8.PubMedCrossRef

42.

Raoul JL, Le Prise E, Meunier B, Julienne V, Etienne PL, Gosselin M, Launois B. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 1995;37:174–176. doi:10.1136/gut.37.2.174.PubMedCrossRef

43.

Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133–1136. doi:10.1016/S0003-4975(99)00974-1.PubMedCrossRef

Title: Use of Positron Emission Tomography in Surgery Follow-Up of Esophageal Cancer
Authors: P. Teyton
J. P. Metges
A. Atmani
V. Jestin-Le Tallec
A. Volant
D. Visvikis
J. P. Bail
O. Pradier
P. Lozac’h
Catherine Cheze Le Rest
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 3/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0749-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Use of Positron Emission Tomography in Surgery Follow-Up of Esophageal Cancer

Abstract

Introduction

Materials and Methods

Results and Discussion

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Materials and Methods

Results and Discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2009

Laparoscopic Esophagomyotomy for Achalasia: How I Do It

Intestinal Afferent Nerve Sensitivity is Increased During the Initial Development of Postoperative Ileus in Mice

Totally Transumbilical Laparoscopic Cholecystectomy

The Incidental Asymptomatic Pancreatic Lesion: Nuisance or Threat?

Validation of an English Version of the Padova Quality of Life Instrument to Assess Quality of Life Following Ileal Pouch Anal Anastomosis

Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis?